PayagalaSPozniakA. The global burden of HIV. Clin Dermatol2024; 42(2): 119–127. DOI: 10.1016/j.clindermatol.2024.02.001.
2.
Di PerriG. Pharmacological outlook of lenacapavir: a novel first-in-class long-acting HIV-1 capsid inhibitor. Infez Med2023; 31(4): 495–499. DOI: 10.53854/liim-3104-8.
U.S. Food and Drug Administration. FDA approves new HIV drug for adults with limited treatment options (press release). Silver Spring, MD: U.S. Food and Drug Administration (FDA), 2022. Archived from the original on 15 January 2023. Retrieved 23 December 2022. This article incorporates text from this source, which is in the public domain.
5.
National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
6.
MatosFBMbanzeDGomesP, et al.Effective management of multidrug-resistant HIV with lenacapavir and fostemsavir: a case study. Int J STD AIDS2025; 36(2): 161–163. DOI: 10.1177/09564624241296583.
7.
MargotNVanderveenLNaikV, et al.Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. J Antimicrob Chemother2022; 77(4): 989–995. DOI: 10.1093/jac/dkab503.
8.
GandhiMPoiMLeeSA. Lenacapavir: a novel long-acting agent for HIV treatment and prevention. The Lancet HIV2022; 9(2): e92–e95.
